Veradermics, Incorporated (NYSE: MANE) has reported positive topline results from the female treatment arms of Study ‘207’, an open-label Phase 2 trial of VDPHL01 — the company’s extended-release oral minoxidil tablet — in women with mild-to-moderate androgenetic alopecia. The trial met its primary endpoint.
What the Study Showed
In the female arms, once-daily oral VDPHL01 produced a statistically significant and clinically meaningful increase in nonvellus target area hair count at week 24, measured as change from baseline — the trial’s primary efficacy endpoint. These are the first controlled efficacy data for VDPHL01 in women; to date, pivotal results had been reported only in men, in the Phase 2/3 Study ‘302’.
“These results reinforce our confidence in VDPHL01’s potential to become a foundational treatment for the millions of women living with androgenetic alopecia.”
Reid Waldman, M.D., Chief Executive Officer, Veradermics
Investor Conference Call
Veradermics is hosting an investor call and live webcast to review the results.
| Date | Wednesday, July 15, 2026 |
| Time | 8:00 a.m. ET |
| Format | Investor call and live webcast, with accompanying slides |
| Access | Events page, Investors section of the Veradermics website |
| Replay | Available following the call |
About VDPHL01
VDPHL01 is an investigational, non-hormonal oral treatment in Phase 3 development for pattern hair loss in women and men. Its extended-release formulation is designed to deliver minoxidil with a more consistent exposure profile, avoiding the peak concentrations associated with the dose-limiting cardiovascular effects of conventional oral minoxidil. The company reports the earliest expiring patent term as 2043.
Sources: FemTech Insider; Veradermics via Business Wire (July 14, 2026).